How Blood Proteomics Is Accelerating Neuro Drug Discovery

How Blood Proteomics Is Accelerating Neuro Drug Discovery

Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades^1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options^2,3. Gradual onset, overlapping symptoms and biological heterogeneity complicate both diagnosis and therapeutic development. In response, blood-based biomarkers have emerged as a promising solution, offering a more accessible, scalable way to detect, monitor, and stratify disease⁴.

The translational promise of blood-based biomarkers

Compared to cerebrospinal fluid (CSF) sampling or neuroimaging, blood tests are minimally invasive and cost-effective. The FDA’s 2025 approval of the first blood-based in vitro diagnostic for Alzheimer’s disease (AD) highlights growing confidence in the circulating proteome as a clinically informative matrix⁵.

Accelerating this shift toward investigating the plasma proteome, the Global Neurodegeneration Proteomics Consortium (GNPC) released one of the most harmonized proteomics datasets to date². Publicly released in July 2025, the GNPC Version 1 (V1) dataset comprises more than 250 million protein measurements generated from serum, plasma and CSF samples collected from 18,645 individuals across AD, Parkinson’s disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

In the Nature Medicine publication accompanying the GNPC V1 release, the authors present three use cases demonstrating how plasma proteomics can interrogate key biological questions in neurodegenerative and aging research². Using the GNPC dataset, they show that plasma proteomic profiles:

1. Indicate both disease status and severity, showing strong associations with disease type and clinical progression;
2. Reflect disease-specific patterns of premature aging, based on plasma proteomic organ aging models;
3. Correlate with APOE ε4 carrier status, helping distinguish AD-specific effects from APOE genotype-related pathways.

Scalable discovery: Profiling 10,000+ proteins from just 55 μL of plasma

To support high-resolution plasma proteomic analysis, GNPC selected the SomaScan™ Assay as the primary platform (Figure 1) ². With unmatched breadth, the latest SomaScan™ 11K Assay simultaneously measures over 10,000 human proteins – including low-abundance proteins – without the need for depletion or enrichment.

Unlike other affinity-based platforms, it does not require bridging samples across batches or sites, streamlining workflows and data analysis for multi-center and longitudinal clinical trials. In a recent independent comparison of eight proteomics platforms, the SomaScan Assay demonstrated the highest analytical precision and the most comprehensive coverage of FDA-approved plasma protein biomarkers⁶.

Antibodies: The “hidden” 20% of the plasma proteome

Comprising roughly 20% of the plasma proteome by mass, antibodies play critical roles in disease pathology and treatment response. Their stability over time and sensitivity to physiological changes make them ideal candidates for longitudinal biomarkers and pharmacodynamic monitoring. Yet traditional proteomics methods offer limited access to antibody–antigen interactions at scale.

The KREX™ Assay addresses this gap with highly multiplexed autoantibody (AAb) profiling against more than 1,800 full-length, properly folded human proteins. This enables biologically relevant antibody–antigen binding, revealing which proteins the immune system flags as “abnormal” and how it responds to disease or therapy. These insights help uncover early immune dysregulation, enable patient stratification and inform immune-targeted therapeutic strategies.

Selected studies illustrating the translational value of AAb profiling in neurodegeneration include:

• Potential early diagnostic biomarkers: Six AAbs elevated in patients with mild AD compared to non-AD dementia, several targeting proteins involved in cognitive decline and Tau phosphorylation⁷.
• Potential immune-targeted intervention biomarkers: Eight AAbs elevated in PD patients seropositive for Helicobacter pylori, supporting epidemiological links between the pathogen and worsened motor symptoms⁸.

A new era for neurodegenerative research

As pharmaceutical pipelines shift toward precision and predictive biomarkers, high-plex plasma proteomics is uncovering real-time, actionable insights into disease biology. While this article focused on neurodegeneration, circulating molecular signatures are increasingly recognized as valuable across a broader spectrum of CNS disorders, including autism spectrum disorder and psychiatric conditions.

Standard BioTools™ supports translational and clinical research through scalable services for SomaScan and KREX Assays. By delivering high-quality, reproducible data from small sample volumes, we help pharmaceutical teams like yours advance biomarker-driven strategies – from bench to bedside.